Takeda Pharmaceutical Company Limited (TKPHF) Research

Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. This includes the research, development, production, commercialization, and external licensing of its pharmaceutical products across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and other parts of Asia. The company concentrates its therapeutic endeavors on key medical areas such as digestive health (gastroenterology), rare disorders, treatments derived from blood plasma, cancer care (oncology), and neurological conditions. Its extensive portfolio features numerous well-known brands, including Entyvio, Takhzyro, Velcade, Livtencity, and Dexilant, among others. Takeda actively cultivates a wide-ranging network of strategic partnerships and collaborations. This includes out-licensing agreements, for example with Neurocrine Biosciences, Inc.; in-licensing deals and research collaborations with organizations like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and joint research efforts with companies such as Crescendo Biologics and Skyhawk Therapeutics. Furthermore, Takeda maintains strategic alliances with entities like Evotec SE and KSQ Therapeutics, underscoring its commitment to external innovation.

Open Takeda Pharmaceutical Company Limited (TKPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.